Format

Send to

Choose Destination
J Am Acad Dermatol. 2019 Sep 26. pii: S0190-9622(19)32787-2. doi: 10.1016/j.jaad.2019.09.042. [Epub ahead of print]

Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2).

Author information

1
Department of Dermatology, Mount Sinai Hospital, New York, NY. Electronic address: lebwohl@aol.com.
2
Central Dermatology and Saint Louis University School of Medicine, St. Louis, MO.
3
National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD.
4
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY.
5
Sun Pharmaceutical Industries, Inc., Princeton, NJ.
6
Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX.
PMID:
31563641
DOI:
10.1016/j.jaad.2019.09.042
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center